Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2009 1
2010 1
2014 1
2015 2
2016 8
2017 12
2018 9
2019 21
2020 25
2021 24
2022 34
2023 33
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

156 results

Results by year

Filters applied: . Clear all
Page 1
Final phase I substudy results of ivosidenib in patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome.
DiNardo CD, Roboz GJ, Watts JM, Madanat YF, Prince GT, Baratam P, de Botton S, Stein AS, Foran JM, Arellano ML, Sallman DA, Hossain M, Marchione DM, Bai X, Patel PA, Kapsalis SM, Garcia-Manero G, Fathi AT. DiNardo CD, et al. Among authors: sallman da. Blood Adv. 2024 Apr 19:bloodadvances.2023012302. doi: 10.1182/bloodadvances.2023012302. Online ahead of print. Blood Adv. 2024. PMID: 38640348
Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes.
Aguirre LE, Jain A, Ball S, Ali NA, Volpe VO, Tinsley-Vance S, Sallman D, Sweet K, Lancet J, Padron E, Yun S, Kuykendall A, Komrokji R. Aguirre LE, et al. Among authors: sallman d. Clin Lymphoma Myeloma Leuk. 2024 Mar 11:S2152-2650(24)00108-3. doi: 10.1016/j.clml.2024.03.001. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38548563
Hypomethylating Agents and Venetoclax for Acute Myeloid Leukemia Relapsed After Hematopoietic Stem Cell Transplant.
Ionescu F, David JC, Ravichandran A, Sallman DA, Sweet K, Komrokji RS, Chan O, Kuykendall A, Padron E, Faramand R, Bejanyan N, Khimani F, Elmariah H, Pidala J, Mishra A, Perez L, Nishihori T, Lancet JE. Ionescu F, et al. Among authors: sallman da. Clin Lymphoma Myeloma Leuk. 2024 Feb 12:S2152-2650(24)00064-8. doi: 10.1016/j.clml.2024.02.005. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38429222
Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia.
Jain AG, Ball S, Aguirre L, Al Ali N, Kaldas D, Tinsley-Vance S, Kuykendall A, Chan O, Sweet K, Lancet JE, Padron E, Sallman DA, Komrokji R. Jain AG, et al. Among authors: sallman da. Haematologica. 2024 Feb 1. doi: 10.3324/haematol.2023.283661. Online ahead of print. Haematologica. 2024. PMID: 38299605 Free article.
Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk NPM1-mutated AML.
Chan O, Al Ali N, Tashkandi H, Ellis A, Ball S, Grenet J, Hana C, Deutsch Y, Zhang L, Hussaini M, Song J, Yun S, Talati C, Kuykendall A, Padron E, Walker A, Roboz G, Desai P, Sallman D, Sweet K, Komrokji R, Lancet J. Chan O, et al. Among authors: sallman d. Blood Adv. 2024 Mar 12;8(5):1075-1083. doi: 10.1182/bloodadvances.2023011173. Blood Adv. 2024. PMID: 38170740 Free PMC article.
TP53 variant allele frequency and therapy-related setting independently predict survival in myelodysplastic syndromes with del(5q).
Tefferi A, Fleti F, Chan O, Al Ali NH, Al-Kali A, Begna KH, Foran JM, Badar T, Khera N, Shah M, Hiwase D, Padron E, Sallman DA, Pardanani A, Arber DA, Orazi A, Reichard KK, He R, Ketterling RP, Gangat N, Komrokji R. Tefferi A, et al. Among authors: sallman da. Br J Haematol. 2024 Apr;204(4):1243-1248. doi: 10.1111/bjh.19247. Epub 2023 Dec 11. Br J Haematol. 2024. PMID: 38083865
Novel immunotherapies in the treatment of AML: is there hope?
Subklewe M, Bücklein V, Sallman D, Daver N. Subklewe M, et al. Among authors: sallman d. Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):691-701. doi: 10.1182/hematology.2023000455. Hematology Am Soc Hematol Educ Program. 2023. PMID: 38066884
156 results